Browse News
Filter News
Found 251 articles
-
Kura Oncology to Participate in Stifel Targeted Oncology Forum
4/10/2024
Kura Oncology, Inc. today announced its participation in Stifel 2024 Targeted Oncology Forum.
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 5, 2024
4/5/2024
Kura Oncology, Inc. today announced that on April 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 49,500 shares of common stock to four (4) new employees.
-
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
3/6/2024
Kura Oncology, Inc. today announced dosing of the first patient with KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with the tyrosine kinase inhibitor (TKI) cabozantinib in the clear cell renal cell carcinoma (ccRCC) cohort of the Phase 1 portion of the FIT-001 trial.
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2024
3/1/2024
Kura Oncology, Inc. announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase 93,000 shares of common stock to two new employees under the Company’s 2023 Inducement Option Plan.
-
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
2/27/2024
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2023 financial results and provided a corporate update.
-
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
2/26/2024
Kura Oncology, Inc. today announced that the first patient has been dosed in KOMET-008, the Company’s Phase 1 trial of its menin inhibitor ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML).
-
Kura Oncology to Participate in Three Upcoming March 2024 Investor Conferences
2/22/2024
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.
-
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
2/20/2024
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024.
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/2/2024
Kura Oncology, Inc. today announced that on February 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 59,750 shares of common stock to three (3) new employees.
-
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
1/30/2024
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preliminary clinical data from the first 20 patients in KOMET-007.
-
Kura Oncology Announces Oversubscribed $150 Million Private Placement
1/24/2024
Kura Oncology, Inc. today announced that it has agreed to sell 1,376,813 shares of its common stock at a price of $17.25 per share, representing a premium of approximately 29% to Kura’s closing price on January 23, 2024.
-
Immunome Appoints Carol A. Schafer to Board of Directors
1/2/2024
Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced the appointment of Carol A. Schafer to its Board of Directors.
-
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
12/8/2023
Kura Oncology, Inc. (NASDAQ: KURA) and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.
-
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
11/28/2023
Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit at 2:00 p.m. ET / 11:00 a.m. PT on Tuesday, December 5, 2023.
-
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
11/13/2023
IO Biotech announced the appointment of Helen Collins, MD, to its board of directors.
-
IO Biotech Announces 2023 Third Quarter Results
11/13/2023
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® technology platform, today reported financial results for the third quarter ended September 30, 2023.
-
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
11/2/2023
Kura Oncology, Inc. and Mirati Therapeutics, Inc. announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor, and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer.
-
Kura Oncology Reports Third Quarter 2023 Financial Results
11/2/2023
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported third quarter 2023 financial results and provided a corporate update.
-
Kura Oncology to Participate in Three Upcoming Investor Conferences - October 30, 2023
10/30/2023
Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.
-
Kura Oncology to Report Third Quarter 2023 Financial Results
10/26/2023
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023.